Becton, Dickinson and Company (BDX) Stock Rating Reaffirmed by Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of Becton, Dickinson and Company (NYSE:BDX) in a research note released on Friday, November 3rd, Marketbeat.com reports. The firm currently has a $230.00 target price on the medical instruments supplier’s stock, up from their prior target price of $210.00.

BDX has been the topic of a number of other reports. BidaskClub upgraded Becton, Dickinson and from a hold rating to a buy rating in a report on Monday, August 14th. Zacks Investment Research upgraded Becton, Dickinson and from a hold rating to a buy rating and set a $234.00 price objective on the stock in a research note on Tuesday, October 31st. Cowen and Company restated an outperform rating and set a $230.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Barclays PLC restated an equal weight rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Finally, Wells Fargo & Company began coverage on Becton, Dickinson and in a research note on Friday, September 22nd. They set an outperform rating and a $225.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $217.08.

Becton, Dickinson and (NYSE BDX) traded down $2.60 during trading on Friday, hitting $224.23. The company’s stock had a trading volume of 1,161,293 shares, compared to its average volume of 1,322,929. The company has a market cap of $51,030.00, a PE ratio of 23.34, a price-to-earnings-growth ratio of 1.73 and a beta of 1.04. Becton, Dickinson and has a 52-week low of $161.29 and a 52-week high of $227.50. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same period last year, the business earned $2.12 EPS. Becton, Dickinson and’s quarterly revenue was down 2.0% compared to the same quarter last year. sell-side analysts expect that Becton, Dickinson and will post 10.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://baseballnewssource.com/markets/becton-dickinson-ands-bdx-sector-perform-rating-reiterated-at-royal-bank-of-canada/1755425.html.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a $0.75 dividend. The ex-dividend date is Thursday, December 7th. This represents a $3.00 annualized dividend and a yield of 1.34%. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s dividend payout ratio (DPR) is 62.80%.

In other Becton, Dickinson and news, insider Stephen Sichak sold 11,787 shares of the firm’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the completion of the transaction, the insider now owns 14,038 shares in the company, valued at approximately $2,814,057.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of BDX. BlackRock Inc. boosted its position in shares of Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares during the last quarter. Koch Industries Inc. boosted its position in shares of Becton, Dickinson and by 45,268.7% during the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after acquiring an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC bought a new stake in shares of Becton, Dickinson and during the 2nd quarter valued at about $225,164,000. Finally, Janus Henderson Group PLC boosted its position in shares of Becton, Dickinson and by 1,265.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after acquiring an additional 1,122,191 shares during the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.